Literature DB >> 8813133

Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction.

R Bai1, R E Schwartz, J A Kepler, G R Pettit, E Hamel.   

Abstract

The antimitotic depsipeptide cryptophycin 1 (CP1) was compared to the antimitotic peptide dolastatin 10 (D10) as an antiproliferative agent and in its interactions with purified tubulin. The potent activity of CP1 as an inhibitor of cell growth was confirmed. The agent had an IC50 of 20 pM against L1210 murine leukemia cells versus 0.5 nM for D10. Both drugs were comparable as inhibitors of the glutamate-induced assembly of purified tubulin, with D10 being slightly more potent. CP1, like D10, was a noncompetitive inhibitor of the binding of [3H]vinblastine to tubulin (apparent Ki, 3.9 microM); and the depsipeptide was a competitive inhibitor of the binding of [3H]D10 to tubulin (apparent Ki, 2.1 microM). CP1 was less potent than D10 as an inhibitor of nucleotide exchange on tubulin, but the two drugs were equivalent in stabilizing the colchicine binding activity of tubulin. CP1, like D10, caused the formation of extensive structured aggregates of tubulin when present in stoichiometric amounts relative to the protein. Whereas at lower concentrations the drugs were equivalent in causing formation of small oligomers detected by gel permeation high-performance liquid chromatography, there were notable differences in the aggregation reactions induced by the two drugs. The electron micrographic appearance of the D10-induced aggregate differed substantially from that of the CP1-induced aggregate. With D10, but not CP1, aggregate morphology was greatly altered in the presence of microtubule-associated proteins. Finally, although CP1 caused the formation of massive aggregates, as did D10, there was little turbidity change with the depsipeptide as opposed to the peptide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8813133

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Antimicrotubular drugs binding to vinca domain of tubulin.

Authors:  Suvroma Gupta; Bhabatarak Bhattacharyya
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

2.  Interactions of halichondrin B and eribulin with tubulin.

Authors:  Ruoli Bai; Tam Luong Nguyen; James C Burnett; Onur Atasoylu; Murray H G Munro; George R Pettit; Amos B Smith; Rick Gussio; Ernest Hamel
Journal:  J Chem Inf Model       Date:  2011-05-13       Impact factor: 4.956

Review 3.  Drugs that target dynamic microtubules: a new molecular perspective.

Authors:  Richard A Stanton; Kim M Gernert; James H Nettles; Ritu Aneja
Journal:  Med Res Rev       Date:  2011-03-04       Impact factor: 12.944

4.  Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.

Authors:  D Panda; K DeLuca; D Williams; M A Jordan; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

5.  Interaction of diazonamide A with tubulin.

Authors:  Ruoli Bai; Zobeida Cruz-Monserrate; William Fenical; George R Pettit; Ernest Hamel
Journal:  Arch Biochem Biophys       Date:  2019-12-09       Impact factor: 4.013

6.  Tryprostatin A, a specific and novel inhibitor of microtubule assembly.

Authors:  T Usui; M Kondoh; C B Cui; T Mayumi; H Osada
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

7.  Computational predictions of volatile anesthetic interactions with the microtubule cytoskeleton: implications for side effects of general anesthesia.

Authors:  Travis J A Craddock; Marc St George; Holly Freedman; Khaled H Barakat; Sambasivarao Damaraju; Stuart Hameroff; Jack A Tuszynski
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

8.  HIV-1 rev depolymerizes microtubules to form stable bilayered rings.

Authors:  N R Watts; D L Sackett; R D Ward; M W Miller; P T Wingfield; S S Stahl; A C Steven
Journal:  J Cell Biol       Date:  2000-07-24       Impact factor: 10.539

9.  Antiproliferative Activity of Crocin Involves Targeting of Microtubules in Breast Cancer Cells.

Authors:  Rupali R Hire; Shalini Srivastava; Melissa B Davis; Ananda Kumar Konreddy; Dulal Panda
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

10.  Novel unit B cryptophycin analogues as payloads for targeted therapy.

Authors:  Eduard Figueras; Adina Borbély; Mohamed Ismail; Marcel Frese; Norbert Sewald
Journal:  Beilstein J Org Chem       Date:  2018-06-01       Impact factor: 2.883

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.